title: Preferential and persistent depletion of CCR5+ T-helper lymphocytes with nonlymphoid homing potential despite early treatment of primary HIV infection.
abstract: Strains of human immunodeficiency virus (HIV) transmitted between individuals use the CCR5 coreceptor, but no preferential depletion of particular Th-lymphocyte subpopulations has been reported during primary HIV infection (PHI). In contrast, gut-associated Th lymphocytes are preferentially depleted in macaques recently infected by simian immunodeficiency virus. The expression of CCR5 and the intestinal homing receptor integrin alpha4beta7 on subpopulations of Th lymphocytes was studied in 12 patients with PHI. There was a profound decrease of circulating alpha4beta7+ Th lymphocytes and CCR5+ memory Th lymphocytes with nonlymphoid homing potential (CD62L-CD45RO+). Unlike other Th lymphocytes, this cell population remained depleted despite early control of viral replication under antiretroviral treatment. Therefore, HIV preferentially targets a specific CCR5+ subpopulation of Th lymphocytes early during infection, inducing its persistent depletion despite treatment. Protective immunity in vivo depends on Th lymphocytes carrying homing capacity to nonlymphoid tissue, and therefore these data may explain the persistent abnormalities of immune functions in patients infected with HIV.
authors.affiliation: INSERM U131 and Service de Médecine Interne et d'Immunologie Clinique, Service de Microbiologie-Immunologie, Hôpital Antoine Béclère, Institut Paris-Sud sur les Cytokines, Clamart, France.
authors.forename: R
authors.initials: R
authors.lastname: Krzysiek
authors.forename: A
authors.initials: A
authors.lastname: Rudent
authors.forename: L
authors.initials: L
authors.lastname: Bouchet-Delbos
authors.forename: A
authors.initials: A
authors.lastname: Foussat
authors.forename: C
authors.initials: C
authors.lastname: Boutillon
authors.forename: A
authors.initials: A
authors.lastname: Portier
authors.forename: D
authors.initials: D
authors.lastname: Ingrand
authors.forename: D
authors.initials: D
authors.lastname: Sereni
authors.forename: P
authors.initials: P
authors.lastname: Galanaud
authors.forename: L
authors.initials: L
authors.lastname: Grangeot-Keros
authors.forename: D
authors.initials: D
authors.lastname: Emilie
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D016023:Integrins / Q000032:analysis*; D007422:Intestines / Q000276:immunology; D019041:L-Selectin / Q000032:analysis; D017493:Leukocyte Common Antigens / Q000032:analysis; D009928:Organ Specificity; D019713:Receptors, CCR5 / Q000032:analysis*; D016201:Receptors, Lymphocyte Homing / Q000032:analysis*; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000473:pathology* / Q000821:virology; D006377:T-Lymphocytes, Helper-Inducer / Q000737:chemistry / Q000473:pathology* / Q000821:virology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D016023:Integrins; D019713:Receptors, CCR5; D016201:Receptors, Lymphocyte Homing; C071777:integrin alpha4beta7; D019041:L-Selectin; D017493:Leukocyte Common Antigens